Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen
Status:
COMPLETED
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
The study should evaluate the biological distribution of \[177Lu\]Lu-BQ7876 in patients with prostate cancer.
The objective are:
1. To evaluate the content of \[177Lu\]Lu-BQ7876 in the blood of patients with prostate cancer at different time points after a single intravenous administration.
2. To assess the distribution of \[177Lu\]Lu-BQ7876 in normal tissues and tumors at different time points.
3. To evaluate dosimetry of \[177Lu\]Lu-BQ7876.
4. To study the safety and tolerability of the drug \[177Lu\]Lu-BQ7876 after a single injection.
Phase:
PHASE1
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences